Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Manali says third-line DLBCL still favors CD19 CAR T when patients are eligible and CAR-naive, because about 40% have a flat five-year curve suggesting cure. Bispecifics show durable complete responses at three years, but follow-up is shorter. She sequences CAR T first, then a CD20 bispecific.

Related Insights

In relapsed/refractory DLBCL, the timing of relapse is a critical factor in determining the next line of therapy. Patients who relapse within 12 months are preferred candidates for CAR-T therapy. Those relapsing after 12 months may first undergo salvage chemotherapy followed by an autologous stem cell transplant if they respond.

For third-line follicular lymphoma, where both CAR-T and bispecifics are approved, experts are leaning towards CAR-T. The long-term follow-up data for CAR-T suggests a potential for cure, making it a more compelling option for eligible patients despite logistical challenges.

An exploratory strategy for DLBCL patients involves using ctDNA to detect minimal residual disease after CAR T-cell therapy. This allows for early intervention with bispecific antibodies when the disease burden is low, potentially preventing full clinical progression, a shift from reactive to proactive treatment.

In follicular lymphoma, the treatment goal is durable remission with manageable toxicity, not necessarily a cure. Therefore, clinicians frequently prefer using a bispecific antibody first, reserving the more complex and toxic CAR-T cell therapy for transformed disease or after a bispecific fails.

For DLBCL patients awaiting CAR-T cell therapy, particularly those with aggressive disease, bispecific antibodies are the preferred bridging strategy. This approach effectively controls disease and reduces tumor burden for better CAR-T outcomes, while avoiding the T-cell depleting effects of traditional chemotherapy.

Rather than viewing bispecific antibodies and CAR-T cell therapy as mutually exclusive, Dr. Budde uses bispecific combinations as an off-the-shelf bridging strategy. High tumor burden and refractory disease reduce CAR-T response rates; administering an initial truncated course of bispecific combinations debulks aggressive lymphoma into deep remissions before transitioning patients to single-infusion CAR-T to complete treatment.

The TRANSFORM study quantifies the critical importance of therapy timing. DLBCL patients receiving Liso-cel CAR-T as a second-line treatment had a 95% two-year overall survival, which dropped significantly to 78% for patients who received it third-line after crossover from the standard-of-care arm.

Prior CAR T-cell therapy does not compromise the clinical efficacy of CD20 x CD3 bispecific antibodies in diffuse large B-cell lymphoma. In phase 2 trials, epcoritamab achieved a 36% complete remission rate in post-CAR T patients compared to 39% overall. Similarly, glofitumab demonstrated complete remission rates in patients with prior CAR T exposure comparable to those who were CAR T-naive, with durable remissions observed in both groups.

Moving CAR T-cell therapy from the third-line to the second-line setting for high-risk DLBCL doesn't just improve survival curves, it meaningfully increases the cure fraction from approximately 40% to 50-55%. This quantifiable benefit provides a strong rationale for using CAR T therapy earlier in the disease course.

Long-term follow-up from the pivotal epcoritamab trial reveals that 46% of DLBCL patients who achieve a complete remission maintain it at four years. This durability provides strong evidence that bispecific monotherapy, not just CAR-T, can be a curative treatment for a subset of patients.